Editorial commentary: Early high-dose daptomycin for methicillin-resistant staphylococcus aureus bloodstream infections with elevated vancomycin minimum inhibitory concentrations: Ready for prime time?

Clinical Infectious Diseases

Volumn 56, Issue 11, 2013, Pages 1570-1572

  Weston, Adam ^a   Boucher, Helen W ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

bloodstream infection; daptomycin; methicillin resistant Staphylococcus aureus; MRSA; vancomycin

Indexed keywords

DAPTOMYCIN; VANCOMYCIN; ANTIINFECTIVE AGENT;

ANTIBIOTIC THERAPY; BLOODSTREAM INFECTION; DRUG COST; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TREATMENT FAILURE; HUMAN; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; NOTE; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; BACTEREMIA; DRUG EFFECT; FEMALE; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; DRUG EFFECTS; STAPHYLOCOCCAL INFECTIONS;

BLOODSTREAM INFECTION; DAPTOMYCIN; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MRSA; VANCOMYCIN;

ANTI-BACTERIAL AGENTS; BACTEREMIA; DAPTOMYCIN; FEMALE; HUMANS; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCAL INFECTIONS; VANCOMYCIN;

EID: 84877355862     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cit118     Document Type: Note

References (16)

1. Murray KP, Zhao J, Davis SL, et al. Early use of daptomycin versus vancomycin for methicillin-resistant Staphylococcus aureus bacteremia with vancomycin minimum inhibitory concentration 1 mg/L: a matched cohort study [published online ahead of print 28 February 2013]. Clin Infect Dis 2013; 56:1562-9.
2. van Hal SJ, Lodise TP, Paterson DL. The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: a systematic review and meta-analysis. Clin Infect Dis 2012; 54:755-71.
3. Holland TL, Fowler VG. Vancomycin minimum inhibitory concentration and outcome in patients with Staphylococcus aureus bacteremia: pearl or pellet? J Infect Dis 2011; 204:329-31.
4. Holmes NE, Turnidge JD, Munckhof WJ, et al. Antibiotic choice may not explain poorer outcomes in patients with Staphylococcus aureus bacteremia and high vancomycin minimum inhibitory concentrations. J Infect Dis 2012; 204:340-7.
5. Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin- resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011; 52:285-92.
6. Moore CL, Osaki-Kiyan P, Haque NZ, Perri MB, Donabedian S, Zervos MJ. Daptomycin versus vancomycin for bloodstream infections due to methicillin-resistant Staphylococcus aureus with a high vancomycin minimum inhibitory concentration: a casecontrol study. Clin Infect Dis 2012; 54:51-8.
7. Wu G, Abraham T, Rapp J, Vastey F, Saad NBalmir E. Daptomycin: evaluation of a high-dose treatment strategy. Int J Antimicrob Agents 2011; 38:192-6.
8. Lai CC, Sheng WH, Wang JT, et al. Safety and efficacy of high-dose daptomycin as salvage therapy for severe gram-positive bacterial sepsis in hospitalized adult patients. BMC Infect Dis 2013; 13:66.
9. Kullar R, Davis SL, Levine DP, et al. Highdose daptomycin for treatment of complicated gram-positive infections: a large, multicenter, retrospective study. Pharmacotherapy 2011; 31:527-36.
10. Bhavnani SM, Rubino CM, Ambrose PG, Drusano GL. Daptomycin exposure and the probability of elevations in the creatine phosphokinase level: data from a randomized trial of patients with bacteremia and endocarditis. Clin Infect Dis 2010; 50:1568-74.
11. Food Drug Administration. Label and approval history 11/30/2010. Available at: http://www.accessdata.fda.gov/drugsatfda-docs/appletter/2010/ 021572s022,s023,s024,s027,s030,s032ltr.pdf. Accessed 18 August 2011.
12. Cubicin (Daptomycin). Package insert 11/30/2010. Available at: http://www.accessdata.fda.gov/drugsatfda-docs/label/2010/ 021572s022s023s024s027s030s032lbl.pdf. Accessed 15 August 2011.
13. Fowler VGJ, Boucher HW, Corey GR, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 2006; 355:653-65.
14. Levine DP, Fromm BS, Reddy BR. Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis. Ann Intern Med 1991; 115:674-80.
15. Nadarajah R, Post LR, Liu C, Miller SA, Sahm DF, Brooks GF. Detection of vancomycin-intermediate Staphylococcus aureus with the updated Trek-Sensititre System and the MicroScan System. Comparison with results from the conventional Etest and CLSI standardized MIC methods. Am J Clin Pathol 2010; 133:844-8.
16. Han JH, Edelstein H, Lautenbach E. Reduced vancomycin susceptibility and staphylococcal cassette chromosome mec (SCCmec) type distribution in methicillinresistant Staphylococcus aureus bacteraemia. J Antimicrob Chemother 2012; 67:2346-9.